POP: Palatability Of Prednisolone

  • Research type

    Research Study

  • Full title

    A study to assess the palatability of prednisolone formulations in children and young adults

  • IRAS ID

    228660

  • Contact name

    Matthew Peak

  • Contact email

    matthew.peak@alderhey.nhs.uk

  • Sponsor organisation

    Alder Hey Children's Hospital NHS Foundation Trust

  • Duration of Study in the UK

    1 years, 0 months, 0 days

  • Research summary

    Liquid medicines have been traditionally considered the most commonly used oral formulation for children, as they are easy to swallow by the patient and doses can be measured at the point of use. However, the taste of paediatric medicines is one of the most important formulation factors which has the potential to influence adherence and compliance to treatment regimens.
    Prednisolone is a routinely given to children. It can be used to treat illnesses such as asthma, arthritis, and kidney/ bowel disease. Although prednisolone is available in tablet form, children often prefer it to be prescribed in liquid form as it is easier to administer.
    At Alder Hey, when a liquid formulation of prednisolone is required for paediatric use, either prednisolone soluble tablets or a prednisolone oral solution can be prescribed and dispensed. When selecting which formulation to prescribe, one of the things that health care professionals take into account is the palatability of the available formulations. The palatability of a medicine is important, especially when considering children as it can impact on the overall experience of taking medicines, on adherence and therefore on health outcomes.
    The proposal describes a study that will identify formulation preference of prednisolone in healthy children and young people (CYP) and NHS paediatric patients, findings from this study will influence future prednisolone prescribing and dispensing within Alder Hey.

  • REC name

    South West - Cornwall & Plymouth Research Ethics Committee

  • REC reference

    17/SW/0185

  • Date of REC Opinion

    25 Sep 2017

  • REC opinion

    Further Information Favourable Opinion